Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In this study, the efficacy and safety of two radotinib doses, 300 mg twice daily and 400 mg
twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients
with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase
(CML-CP).